Date: 2016-05-11
Type of information: Company acquisition
Acquired company: Alizé Pharma II (France)
Acquiring company: Jazz Pharmaceuticals (Ireland)
Amount: up to €18 million
Terms: * On May 11, 2016, Alizé Pharma II announced that a subsidiary of Jazz Pharmaceuticals has acquired 100% of its shares. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million, including an upfront payment of €8 million and potential payments of up to €10 million related to regulatory milestones. The transaction did not involve the transfer of any employees from the Alizé Pharma Group to Jazz Pharmaceuticals.
Details: Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. Prior to its acquisition in March 2016, Alizé Pharma II was focused on the development of pegcrisantaspase (Asparec®), a new pegylated recombinant L-asparaginase in onco-hematological rare diseases. The company was created in 2008. Prior to the closing of this transaction its shareholders were TAB Consulting, Octalfa, CEMA and Sham Innovation Santé. The company’s lead assets are pegcrisantaspase (Asparec®), a pegylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. In February 2012, Alizé Pharma II announced that it had licensed these assets to EUSA Pharma, which was subsequently acquired by Jazz Pharmaceuticals.
Related: Cancer - Oncology Rare diseases
